MON-678 Systematic Review Of The Metabolic Outcomes In Adult Onset Craniopharyngioma

Abstract Disclosure: P. Davies: None. J. Nash: None. H.S. Randeva: None. T.M. Barber: None. P. Natesh: None. Context: Craniopharyngioma is a rare epithelial tumour typically arising in the sellar or suprasellar region of the brain. Craniopharyngioma has a bi-modal age distribution and can be subcategorised into adult-onset (AOCP) and childhood-onset craniopharyngioma (COCP). Whilst histologically benign, these tumours are locally aggressive and damage to structures may occur due to compression by the tumour itself or during treatment. This may lead to hypothalamic obesity and a range of metabolic diseases, including Type 2 Diabetes Mellitus (T2DM), Hypertension (HTN), lipid disorders, and Metabolic Syndrome (MetS). Considering the marked impact of metabolic disease on patients, data regarding metabolic outcomes in AOCP is limited and inconsistently reported. There has been no systematic reviews reporting on metabolic outcomes in AOCP. Aim: This study aimed to systematically review the literature to consolidate evidence of metabolic consequences in AOCP by compiling prevalence data, assessing how metabolic outcomes are reported across the literature, as well as considering how to standardise reporting. Methods: Systematic review was performed following the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) statement. PubMed, Embase, and Scopus were searched for relevant articles. From the database searches 3124 studies were identified. After deduplication and independent review by 2 authors 124 studies were eligible for full text review. Full text review yielded 11 studies eligible for inclusion. The quality of the studies was assessed using the NIH tool and data were extracted. Basic descriptive statistics were performed to determine pooled sample prevalence, range, and mean prevalence across the studies. Results: Initial search retrieved 2295 articles, 11 were included in the study after screening. In total 523 patients were included F=253 (48%). Reporting of metabolic outcomes was heterogeneous throughout the studies. Pooled prevalence was 117/292 (40%) MetS, 75/315 (24%) T2DM, 205/363 (56%) HTN, and 211/425 (50%) lipid disorders. It was not possible to perform meta-analysis due to a lack of data available. A high degree of variability was demonstrated across all the outcomes as shown by the Coefficient of variation. Conclusion: This is the first systematic review of metabolic outcomes in AOCP. Prevalence of metabolic disease was higher than global prevalence figures: MetS 40% vs 12.5%-31.4%, T2DM 24% vs 6.3%, HTN 56% vs 33%. This study appears to solidify and support the relationship between AOCP and the increased prevalence of metabolic disease. Future studies should aim to standardise criteria for reporting metabolic outcomes by using the latest definitions. Future studies can also utilise the International Diabetes Federation Platinum Standard additional metabolic measurements for research. Presentation: Monday, July 14, 2025